|
9
|
| 26 |
IL1B
|
|
increases_expression of
|
NOS2
|
|
| 42 |
SIRT1
|
|
decreases_expression of
|
NOS2
|
if SIRT1 is overexpressed
|
|
19008341
|
Diabetes mellitus, type I
|
|
12
|
| 44 |
IL1B
|
|
increases_expression of
|
NOS2
|
|
| 45 |
SIRT1
|
|
decreases_expression of
|
NOS2
|
if SIRT1 is overexpressed
|
|
19008341
|
Diabetes mellitus, type I
|
|
43
|
| 105 |
NF-kappaB complex
|
|
increases_expression of
|
NOS2
|
and subsequent NO production
|
| 108 |
Doxycycline
|
|
decreases_expression of
|
NOS2
|
and subsequent NO production
|
|
16551748
|
Diabetes mellitus, type I
|
|
58
|
| 173 |
IL1B
|
|
increases_expression of
|
NOS2
|
|
| 176 |
Sulforaphane
|
|
decreases_expression of
|
NOS2
|
in cytokine treated cells
|
| 183 |
NFE2L2
|
|
decreases_expression of
|
NOS2
|
if Nrf2 is overexpressed in cytokine treated cells
|
|
19071154
|
Diabetes mellitus, type I
|
|
67
|
| 205 |
IL1B
|
|
increases_expression of
|
NOS2
|
in pancreatic islets
|
| 207 |
Sulforaphane
|
|
decreases_expression of
|
NOS2
|
in pancreatic islets; in cytokine treated cells
|
|
19071154
|
Diabetes mellitus, type I
|
|
71
|
| 220 |
IL1B
|
|
increases_expression of
|
NOS2
|
|
| 222 |
Troglitazone
|
|
decreases_expression of
|
NOS2
|
in cytokine treated cells
|
| 223 |
Ciglitazone
|
|
decreases_expression of
|
NOS2
|
in cytokine treated cells
|
| 237 |
PPARG
|
|
decreases_expression of
|
NOS2
|
if PPARG is overexpressed in cytokine treated cells
|
| 249 |
NFKBIA-p.S32A-S36A
|
|
decreases_expression of
|
NOS2
|
if overexpressed in cytokine treated cells
|
|
17521952
|
Diabetes mellitus, type I
|
|
98
|
| 325 |
SOD1-p.G93A
|
|
increases_expression of
|
NOS2
|
in microglia cultures
|
| 328 |
SOD1-p.G85R
|
|
increases_expression of
|
NOS2
|
in microglia cultures
|
|
19672969
|
Amyotrophic lateral sclerosis
|
|
200
|
| 17886 |
Anti-M1 peptide IgG
|
|
increases_quantity of
|
NOS2
|
while stimulating cerebral M1 mAChRs
|
| 17887 |
Anti-M1 peptide IgG
|
|
increases_expression of
|
NOS2
|
while stimulating cerebral M1 mAChRs
|
|
19835666
|
Schizophrenia
|
|
370
|
| 1496 |
NOS2
|
|
increases_activity of
|
neuron apoptotic process
|
|
|
16000635
|
Amyotrophic lateral sclerosis
|
|
371
|
| 1499 |
injury by unilateral sciatic nerve avulsion
|
|
decreases_expression of
|
NOS2
|
|
| 1518 |
NOS2
|
|
affects_activity of
|
cellular response to DNA damage stimulus
|
|
|
16000635
|
Amyotrophic lateral sclerosis
|
|
412
|
| 1804 |
IFNG
|
|
increases_quantity of
|
NOS2
|
|
|
19477238
|
Amyotrophic lateral sclerosis
|
|
647
|
| 3438 |
SOD1-mod
|
|
increases_expression of
|
NOS2
|
|
| 3439 |
SOD1-p.G93A
|
|
increases_expression of
|
NOS2
|
|
|
17394546
|
Amyotrophic lateral sclerosis
|
|
672
|
| 3596 |
Status epilepticus
|
|
increases_expression of
|
NOS2
|
in lithium-pilocarpine model
|
|
20149694
|
Status epilepticus
|
|
908
|
| 5536 |
Resveratrol
|
|
decreases_expression of
|
NOS2
|
|
|
19191039
|
Alzheimer disease
|
|
1,086
|
| 6893 |
NOS2
|
|
increases_quantity of
|
NO
|
|
| 6896 |
Lipopolysaccharide
|
|
increases_expression of
|
NOS2
|
|
| 6897 |
Lipopolysaccharide
|
|
increases_quantity of
|
NOS2
|
|
| 6918 |
PARK7
|
|
affects_activity of
|
NOS2
|
via p38MAPK pathway
|
|
19276172
|
Parkinson disease
|
|
1,092
|
| 7239 |
increased circulating free fatty acid level
|
|
increases_expression of
|
NOS2
|
|
| 7240 |
Proinflammatory cytokine
|
|
increases_expression of
|
NOS2
|
|
| 7241 |
response to oxidative stress
|
|
increases_expression of
|
NOS2
|
|
| 7244 |
NOS2
|
|
decreases_quantity of
|
IRS1
|
via increased degradation of IRS1 if NPS2 activity is increased
|
| 45977 |
adipose tissue macrophage
|
|
increases_quantity of
|
NOS2
|
in adipose tissue
|
|
18053812
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,103
|
| 7033 |
F2
|
|
increases_expression of
|
NOS2
|
via activation of microglia in the substantia nigra
|
| 7053 |
SB203580
|
|
decreases_expression of
|
NOS2
|
if expression of INOS has been induced by pKr2
|
| 7056 |
SP600125
|
|
decreases_expression of
|
NOS2
|
if expression of INOS has been induced by pKr2
|
|
20025058
|
Parkinson disease
|
|
1,105
|
| 7012 |
microglial cell activation
|
|
increases_quantity of
|
NOS2
|
|
|
20025058
|
Parkinson disease
|
|
1,124
|
| 7233 |
Lipopolysaccharide
|
|
increases_quantity of
|
NOS2
|
in substantia nigra
|
| 7248 |
NR4A2
|
|
decreases_expression of
|
NOS2
|
following LPS treatment and by recruiting the CoREST-CtBP complex
|
|
19345186
|
Parkinson disease
|
|
1,137
|
| 7398 |
SNCA
|
|
increases_expression of
|
NOS2
|
in microglia
|
|
20511551
|
Parkinson disease
|
|
1,150
|
| 7511 |
MAP3K5
|
|
increases_quantity of
|
NOS2
|
after induction with LPS
|
|
15864310
|
Parkinson disease
|
|
1,176
|
| 7788 |
ob/ob mouse
|
|
increases_expression of
|
NOS2
|
in skeletal muscle
|
| 7798 |
NOS2
|
NOT |
affects_expression of
|
IRS1
|
in skeletal muscle
|
| 13351 |
NOS2
|
|
affects_quantity of
|
IRS1
|
in skeletal muscle
|
|
15805118
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,179
|
| 7801 |
NOS2
|
|
affects_quantity of
|
brown adipose tissue
|
in ob/ob mice
|
| 7804 |
NOS2
|
|
affects_expression of
|
UCP1
|
|
| 7807 |
NOS2
|
|
affects_expression of
|
UCP3
|
|
| 7813 |
NOS2
|
|
affects_activity of
|
Obesity
|
|
| 7814 |
NOS2
|
|
affects_expression of
|
PPARGC1A
|
|
| 7815 |
NOS2
|
|
affects_activity of
|
energy homeostasis
|
in ob/ob mice
|
| 13352 |
NOS2
|
|
affects_expression of
|
SIRT1
|
|
| 13353 |
NOS2
|
|
affects_expression of
|
SIRT3
|
|
| 13354 |
NOS2
|
|
affects_activity of
|
diet induced thermogenesis
|
in ob/ob mice
|
|
20532036
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,182
|
| 7833 |
Peroxynitrite
|
|
increases_expression of
|
NOS2
|
in primary astrocyte monolayers
|
| 7836 |
Lipopolysaccharide
|
|
increases_expression of
|
NOS2
|
in primary astrocyte monolayers
|
| 7837 |
NOS2
|
|
increases_quantity of
|
NO
|
in primary astrocyte monolayers
|
|
11754077
|
Amyotrophic lateral sclerosis
|
|
1,188
|
| 7888 |
obesity, high-fat diet-induced
|
|
increases_expression of
|
NOS2
|
in skeletal muscle, in adipose tissue
|
| 7890 |
obesity, high-fat diet-induced
|
NOT |
increases_expression of
|
NOS2
|
in liver
|
| 7916 |
ZDF rat
|
|
increases_expression of
|
NOS2
|
in skeletal muscle, in adipose tissue
|
| 7917 |
ob/ob mouse
|
|
increases_expression of
|
NOS2
|
in skeletal muscle, in adipose tissue
|
| 7918 |
NOS2
|
|
affects_activity of
|
Insulin resistance
|
|
| 7919 |
NOS2
|
|
affects_activity of
|
improved glucose tolerance
|
|
|
11590438
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,194
|
| 7969 |
Minocycline
|
|
decreases_activity of
|
NOS2
|
|
|
17030375
|
Schizophrenia
|
|
1,207
|
| 13371 |
recruited adipose tissue macrophage
|
|
affects_expression of
|
NOS2
|
|
|
17192460
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,215
|
| 8188 |
microglial cell activation
|
|
increases_quantity of
|
NOS2
|
|
| 8190 |
NOS2
|
|
increases_activity of
|
inflammatory response
|
|
|
17537546
|
Parkinson disease
|
|
1,218
|
| 8196 |
SNCA
|
|
increases_expression of
|
NOS2
|
via microglial cell activation
|
|
17537546
|
Parkinson disease
|
|
1,230
|
| 8263 |
IFNG
|
|
increases_quantity of
|
NOS2
|
in microglia
|
| 8264 |
astrocyte
|
|
decreases_quantity of
|
NOS2
|
in microglia; after induction of iNOS via interferon-gamma
|
|
16467537
|
Parkinson disease
|
CIDeRplus